mkdir -p /tmp/workspace/pharma-quiz && python3 << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import cm from reportlab.platypus import (SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, HRFlowable, PageBreak, KeepTogether) from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_JUSTIFY # ── Data ──────────────────────────────────────────────────────────────────────── chapters = [ { "unit": "UNIT I – General Pharmacology", "chapters": [ { "ch": "1. Introduction to Pharmacology", "topics": [ ("Routes of Drug Administration", "Advantages & disadvantages of each route (oral, IV, IM, SC, sublingual, transdermal, inhalation); first-pass metabolism; bioavailability comparison."), ("Pharmacokinetics – ADME", "Drug absorption factors; protein binding; volume of distribution; zero-order vs first-order kinetics; half-life; steady-state concentration.") ] }, { "ch": "2. Pharmacodynamics", "topics": [ ("Drug Receptors & Receptor Theories", "Types of receptors (G-protein coupled, ion channel, enzyme-linked, nuclear); agonist, antagonist, partial agonist; spare receptors; occupancy theory."), ("Dose-Response Relationship", "Graded vs quantal dose-response curves; ED50, LD50, TD50; therapeutic index; potency vs efficacy; drug tolerance & tachyphylaxis.") ] }, { "ch": "3. Adverse Drug Reactions & Drug Interactions", "topics": [ ("Classification of ADRs", "Type A (augmented) vs Type B (bizarre); idiosyncratic reactions; teratogenicity (pregnancy categories); drug allergy & anaphylaxis management."), ("Pharmacokinetic & Pharmacodynamic Interactions", "Enzyme induction (rifampicin, phenobarbitone) vs inhibition (ketoconazole, erythromycin); CYP450 system; additive, synergistic, antagonistic interactions.") ] }, ] }, { "unit": "UNIT II – Autonomic Nervous System Pharmacology", "chapters": [ { "ch": "4. Cholinergic Pharmacology", "topics": [ ("Cholinomimetic Drugs", "Direct (ACh, pilocarpine, bethanechol, carbachol) vs indirect (physostigmine, neostigmine, organophosphates); uses: glaucoma, myasthenia gravis, Alzheimer's; SLUDD effects."), ("Anticholinergic Drugs", "Atropine pharmacology – effects on each organ; uses & contraindications; scopolamine for motion sickness; glycopyrrolate; atropine poisoning & treatment.") ] }, { "ch": "5. Adrenergic Pharmacology", "topics": [ ("Sympathomimetic Drugs", "Classification (direct, indirect, mixed); adrenaline vs noradrenaline vs isoprenaline actions; dopamine dose-dependent effects; dobutamine; uses in shock & cardiac arrest."), ("Adrenergic Blockers", "Alpha blockers (prazosin, phentolamine) – uses in hypertension, BPH; beta blockers (propranolol, atenolol, carvedilol) – cardioselectivity; uses, contraindications, ISA.") ] }, { "ch": "6. Neuromuscular Blocking Agents & Ganglionic Drugs", "topics": [ ("Neuromuscular Blocking Agents", "Depolarising (succinylcholine – Phase I & II block, fasciculations, hyperkalaemia) vs non-depolarising (vecuronium, atracurium); reversal agents; use in anaesthesia."), ("Ganglionic Blockers & Drugs Acting on Autonomic Ganglia", "Nicotinic receptors at ganglia; hexamethonium mechanism; trimethaphan; clinical relevance; comparison with neuromuscular block.") ] }, ] }, { "unit": "UNIT III – CNS Pharmacology", "chapters": [ { "ch": "7. General Anaesthetics", "topics": [ ("Inhalational Anaesthetics", "MAC concept; stages of anaesthesia (Guedel's stages); halothane vs isoflurane vs sevoflurane vs desflurane; halothane hepatotoxicity; nitrous oxide uses & limitations."), ("Intravenous Anaesthetics", "Thiopentone (ultra-short acting – redistribution); ketamine (dissociative anaesthesia, NMDA antagonism, emergence reactions); propofol; etomidate; midazolam for sedation.") ] }, { "ch": "8. Sedative-Hypnotics & Anxiolytics", "topics": [ ("Benzodiazepines", "GABA-A receptor potentiation; pharmacokinetics (diazepam vs lorazepam vs triazolam); uses – anxiety, epilepsy, alcohol withdrawal, pre-medication; flumazenil reversal."), ("Non-BZD Hypnotics & Barbiturates", "Zolpidem, zopiclone (Z-drugs) – omega-1 selectivity; barbiturates – enzyme induction, porphyria contraindication; barbiturate vs BZD toxicity comparison.") ] }, { "ch": "9. Antiepileptic Drugs", "topics": [ ("Mechanism-Based Classification of AEDs", "Na+ channel blockers (phenytoin, carbamazepine, valproate); GABA enhancement (valproate, vigabatrin, gabapentin); drugs of choice: GTCS, absence, myoclonic, partial seizures."), ("Phenytoin – High-Yield Drug Profile", "Zero-order kinetics; adverse effects (gingival hyperplasia, hirsutism, nystagmus, fetal hydantoin syndrome); drug interactions; therapeutic drug monitoring.") ] }, { "ch": "10. Antipsychotics & Mood Stabilizers", "topics": [ ("Antipsychotic Drugs", "Typical (chlorpromazine, haloperidol) – D2 blockade; atypical (clozapine, risperidone, olanzapine); EPS types (parkinsonism, akathisia, dystonia, tardive dyskinesia); NMS."), ("Lithium & Mood Stabilizers", "Lithium mechanism, narrow therapeutic index, toxicity signs; monitoring renal & thyroid function; carbamazepine & valproate as alternatives; drug interactions.") ] }, { "ch": "11. Antidepressants", "topics": [ ("TCAs, SSRIs, SNRIs", "Amitriptyline (TCA) – anticholinergic effects, cardiotoxicity in overdose; fluoxetine (SSRI) – serotonin syndrome; venlafaxine (SNRI); onset of action paradox; drug interactions."), ("MAO Inhibitors & Atypical Antidepressants", "Phenelzine – tyramine (cheese) reaction; moclobemide (reversible MAOI); mirtazapine (alpha-2 antagonist, sedative); bupropion (dopamine/NE reuptake – smoking cessation).") ] }, { "ch": "12. Opioid Analgesics", "topics": [ ("Opioid Receptor Pharmacology", "Mu, kappa, delta receptors; morphine effects (analgesia, euphoria, respiratory depression, constipation, miosis); tolerance & dependence; equianalgesic doses."), ("Opioid Overdose & Antagonists", "Naloxone – competitive antagonist, short half-life, precipitated withdrawal; naltrexone for alcohol dependence; methadone maintenance therapy; tramadol – mixed mechanism.") ] }, { "ch": "13. NSAIDs & Analgesic-Antipyretics", "topics": [ ("COX Inhibitors", "COX-1 vs COX-2 roles; aspirin (irreversible COX inhibition, antiplatelet dose 75–150 mg); ibuprofen, diclofenac; selective COX-2 inhibitors (celecoxib) – GI sparing but CV risk."), ("Paracetamol & Gout Pharmacology", "Paracetamol mechanism, hepatotoxicity (NAPQI), N-acetylcysteine antidote; allopurinol vs febuxostat vs colchicine vs probenecid – mechanisms and uses in gout.") ] }, ] }, { "unit": "UNIT IV – Cardiovascular Pharmacology", "chapters": [ { "ch": "14. Antihypertensives", "topics": [ ("Classification & Mechanisms", "ACE inhibitors (captopril – cough, angioedema, teratogenic); ARBs (losartan); CCBs (amlodipine, nifedipine, verapamil, diltiazem); diuretics; beta blockers; JNC/ISH guidelines."), ("Special Situations in Hypertension", "Hypertensive emergency (nitroprusside, labetalol, nicardipine); drugs in pregnancy (methyldopa, labetalol, nifedipine); resistant hypertension; drug contraindications.") ] }, { "ch": "15. Anti-anginal Drugs", "topics": [ ("Nitrates", "Glyceryl trinitrate mechanism (NO → cGMP → vasodilation); organic nitrates; tolerance (8-hour nitrate-free interval); headache & reflex tachycardia; contraindication with PDE-5 inhibitors."), ("Beta Blockers & CCBs in Angina", "Propranolol in stable angina (reduces O2 demand); CCBs in vasospastic (Prinzmetal) angina; ranolazine (late Na+ current inhibitor); combination therapy rationale.") ] }, { "ch": "16. Antiarrhythmics", "topics": [ ("Vaughan Williams Classification", "Class I (Na+ channel) – lidocaine, flecainide; Class II (beta blockers); Class III (K+ channel) – amiodarone, sotalol; Class IV (CCBs) – verapamil; digoxin & adenosine special cases."), ("Amiodarone – High Yield", "Broad-spectrum antiarrhythmic; organ toxicities (pulmonary fibrosis, thyroid, hepatic, corneal deposits, photosensitivity, peripheral neuropathy); monitoring requirements; drug interactions.") ] }, { "ch": "17. Heart Failure & Digoxin", "topics": [ ("Digoxin", "Na+/K+-ATPase inhibition → increased intracellular Ca2+; positive inotropy; vagotonic effects; therapeutic index; toxicity signs (yellow vision, arrhythmias); digoxin toxicity management."), ("Modern Heart Failure Pharmacology", "ACE inhibitors, beta blockers, aldosterone antagonists (spironolactone), sacubitril/valsartan (ARNI); ivabradine; SGLT2 inhibitors in HFrEF; diuretics for symptom control.") ] }, { "ch": "18. Anticoagulants & Antiplatelets", "topics": [ ("Heparin & Warfarin", "Heparin – AT-III dependent, UFH vs LMWH, protamine reversal, HIT; warfarin – vitamin K cycle, factors affected (II,VII,IX,X), INR monitoring, drug interactions, antidote."), ("New Oral Anticoagulants & Antiplatelets", "Dabigatran (direct thrombin inhibitor), rivaroxaban/apixaban (factor Xa inhibitors); idarucizumab & andexanet alfa as reversal agents; clopidogrel (P2Y12 inhibitor, prodrug); ticagrelor.") ] }, { "ch": "19. Hypolipidaemic Drugs", "topics": [ ("Statins", "HMG-CoA reductase inhibition; LDL reduction, pleiotropic effects; myopathy/rhabdomyolysis (creatine kinase monitoring); drug interactions (CYP3A4); rosuvastatin vs atorvastatin."), ("Other Lipid-Lowering Agents", "Fibrates (PPARα agonists – TG reduction); niacin (HDL increase, flushing); ezetimibe (NPC1L1 inhibitor); bile acid sequestrants; PCSK9 inhibitors (evolocumab).") ] }, ] }, { "unit": "UNIT V – Respiratory & GI Pharmacology", "chapters": [ { "ch": "20. Antiasthmatic Drugs", "topics": [ ("Bronchodilators", "SABAs (salbutamol – beta-2 agonist, tremor, hypokalaemia) vs LABAs (salmeterol, formoterol); ipratropium (anticholinergic); theophylline – PDE inhibitor, narrow TI, toxicity."), ("Anti-inflammatory Therapy in Asthma", "Inhaled corticosteroids (budesonide, fluticasone) – local ADRs (candidiasis, dysphonia); leukotriene antagonists (montelukast); omalizumab (anti-IgE); step-wise management.") ] }, { "ch": "21. GI Pharmacology", "topics": [ ("Acid Peptic Disease", "PPIs (omeprazole – mechanism, prodrug, irreversible H+/K+-ATPase block) vs H2 blockers (ranitidine, famotidine); H. pylori triple/quadruple therapy regimens; antacids & sucralfate."), ("Laxatives, Antidiarrheals & Antiemetics", "Osmotic (lactulose, MgSO4), stimulant (bisacodyl, senna), bulk (ispaghula); loperamide vs codeine for diarrhoea; ondansetron (5-HT3) for chemotherapy-induced nausea; metoclopramide.") ] }, ] }, { "unit": "UNIT VI – Endocrine Pharmacology", "chapters": [ { "ch": "22. Insulin & Oral Antidiabetics", "topics": [ ("Insulin Preparations", "Ultra-short (lispro, aspart), short (regular), intermediate (NPH), long-acting (glargine, detemir, degludec); insulin resistance; diabetic emergencies – DKA management."), ("Oral Antidiabetic Drugs", "Metformin (biguanide – AMPK activation, lactic acidosis contraindications); sulfonylureas (glibenclamide – hypoglycaemia risk); DPP-4 inhibitors; GLP-1 agonists; SGLT2 inhibitors.") ] }, { "ch": "23. Thyroid Pharmacology", "topics": [ ("Antithyroid Drugs", "Propylthiouracil vs carbimazole/methimazole – mechanisms (block peroxidase ± T4→T3 conversion); radioactive iodine (I-131); Wolff-Chaikoff effect; thyroid storm treatment."), ("Thyroid Hormone Replacement", "Levothyroxine (T4) pharmacokinetics; monitoring TSH; drug interactions (antacids, iron, calcium); hypothyroidism in pregnancy; myxoedema coma management.") ] }, { "ch": "24. Corticosteroids", "topics": [ ("Glucocorticoids", "Mechanism (gene transcription); relative potencies (hydrocortisone vs prednisolone vs dexamethasone vs betamethasone); mineralocorticoid activity comparison; HPA axis suppression."), ("Adverse Effects & Steroid Withdrawal", "Cushing's syndrome, osteoporosis, hyperglycaemia, immunosuppression, peptic ulcer, cataract, avascular necrosis; steroid withdrawal syndrome; alternate day therapy rationale.") ] }, { "ch": "25. Sex Hormones & Contraceptives", "topics": [ ("Oral Contraceptives", "Combined (estrogen + progestin) – monophasic/triphasic; mechanisms (ovulation inhibition, cervical mucus, endometrium); absolute contraindications; pill failure rate; emergency contraception."), ("Androgens & Anabolic Steroids", "Testosterone esters; anabolic vs androgenic effects; antiandrogens (spironolactone, finasteride, flutamide, cyproterone); use in hypogonadism, BPH, male-pattern baldness.") ] }, ] }, { "unit": "UNIT VII – Chemotherapy", "chapters": [ { "ch": "26. Sulfonamides & Quinolones", "topics": [ ("Sulfonamides & Cotrimoxazole", "PABA analogue – folate synthesis inhibition; sulfonamide-trimethoprim synergy (sequential block); uses (UTI, PCP prophylaxis, nocardia); adverse effects (crystalluria, Stevens-Johnson syndrome, kernicterus)."), ("Fluoroquinolones", "DNA gyrase (topoisomerase II) and topoisomerase IV inhibition; ciprofloxacin vs levofloxacin vs moxifloxacin; adverse effects (tendinopathy, QT prolongation, photosensitivity, avoid in children).") ] }, { "ch": "27. Beta-Lactams & Cell Wall Inhibitors", "topics": [ ("Penicillins & Cephalosporins", "Mechanism (PBP binding, transpeptidase inhibition); penicillinase-resistant (oxacillin); beta-lactamase inhibitors (clavulanic acid); cross-reactivity; cephalosporin generations and clinical uses."), ("Vancomycin & Carbapenems", "Vancomycin – D-Ala-D-Ala binding, glycopeptide; Red man syndrome, nephrotoxicity, ototoxicity; MRSA treatment; carbapenems (imipenem/cilastatin, meropenem) – broadest spectrum; ESBL coverage.") ] }, { "ch": "28. Protein Synthesis Inhibitors", "topics": [ ("30S Inhibitors – Aminoglycosides & Tetracyclines", "Aminoglycosides (gentamicin, amikacin) – irreversible binding, nephrotoxicity, ototoxicity, synergy with penicillins; tetracyclines – bacteriostatic, avoid in pregnancy/children (teeth/bone), photosensitivity."), ("50S Inhibitors – Macrolides, Chloramphenicol, Linezolid", "Erythromycin/azithromycin – macrolide; chloramphenicol – grey baby syndrome, aplastic anaemia; linezolid – oxazolidinone, MRSA/VRE; clindamycin – pseudomembranous colitis risk.") ] }, { "ch": "29. Antitubercular Drugs", "topics": [ ("First-Line ATT", "HRZE regimen (isoniazid, rifampicin, pyrazinamide, ethambutol); individual mechanisms; key adverse effects: INH (peripheral neuropathy – B6), rifampicin (enzyme inducer, orange urine), ethambutol (optic neuritis), PZA (hyperuricaemia)."), ("Multidrug-Resistant TB & Drug Combinations", "Definition of MDR-TB, XDR-TB; second-line drugs (fluoroquinolones, bedaquiline, delamanid, linezolid); DOT strategy; Mantoux test interpretation; BCG vaccine.") ] }, { "ch": "30. Antifungal Drugs", "topics": [ ("Polyenes & Azoles", "Amphotericin B – ergosterol binding, nephrotoxicity (lipid formulations), infusion reactions; azoles (fluconazole, itraconazole, voriconazole) – CYP51 (14-alpha demethylase) inhibition; drug interactions."), ("Echinocandins & Topical Antifungals", "Caspofungin – beta-glucan synthase inhibitor; terbinafine – squalene epoxidase inhibitor; griseofulvin – microtubule disruption; nystatin – topical use only; candida vs aspergillus treatment choice.") ] }, { "ch": "31. Antiviral Drugs", "topics": [ ("Anti-Herpes & Anti-Influenza", "Acyclovir – viral thymidine kinase activation, selective toxicity; ganciclovir for CMV; oseltamivir (neuraminidase inhibitor) for influenza; amantadine; herpes zoster treatment."), ("Antiretroviral Therapy", "HIV life cycle targets; NRTIs (tenofovir, emtricitabine), NNRTIs (efavirenz), PIs (lopinavir), INSTIs (dolutegravir, raltegravir); HAART principles; PEP & PrEP regimens.") ] }, { "ch": "32. Antiprotozoal & Anthelmintic Drugs", "topics": [ ("Antimalarial Drugs", "Chloroquine – mechanism (haem polymerisation inhibition), resistance, uses (RA, SLE), retinal toxicity; primaquine (G6PD haemolysis, radical cure of P. vivax); artemisinin combination therapy (ACT); drug prophylaxis."), ("Anthelmintics", "Albendazole/mebendazole – microtubule disruption; ivermectin – Cl- channel (hyperpolarisation); praziquantel – Ca2+ influx, muscle spasm; drug of choice for each: tapeworm, roundworm, filaria, schistosoma.") ] }, { "ch": "33. Anticancer Drugs", "topics": [ ("Alkylating Agents & Antimetabolites", "Cyclophosphamide – haemorrhagic cystitis (mesna prevention), busulfan – pulmonary fibrosis; methotrexate – DHFR inhibitor, leucovorin rescue; 5-FU – thymidylate synthase; cell-cycle specificity."), ("Targeted Therapy & Hormonal Agents", "Imatinib (BCR-ABL inhibitor in CML); trastuzumab (HER2); rituximab (CD20); tamoxifen (SERM – ER+ve breast cancer, endometrial cancer risk); aromatase inhibitors (letrozole, anastrozole).") ] }, ] }, { "unit": "UNIT VIII – Miscellaneous", "chapters": [ { "ch": "34. Immunosuppressants & Immunomodulators", "topics": [ ("Immunosuppressive Drugs", "Cyclosporine (calcineurin inhibitor – nephrotoxicity, hypertension, hirsutism, gingival hyperplasia); tacrolimus; mycophenolate mofetil; azathioprine; use in organ transplantation & autoimmune disease."), ("Biological DMARDs & Interferons", "Infliximab/adalimumab (anti-TNF – TB reactivation risk); methotrexate as DMARD anchor; interferons (alpha for hepatitis, beta for MS); IVIG uses; G-CSF/GM-CSF (filgrastim).") ] }, { "ch": "35. Drugs in Special Populations", "topics": [ ("Drugs in Pregnancy & Lactation", "FDA pregnancy categories (A/B/C/D/X); teratogenic drugs (thalidomide, warfarin, isotretinoin, ACE inhibitors, valproate, methotrexate, aminoglycosides); safe analgesics in pregnancy; drugs contraindicated in lactation."), ("Drugs in Paediatrics & Geriatrics", "Physiological differences affecting pharmacokinetics in neonates; chloramphenicol grey baby syndrome; aspirin – Reye's syndrome; polypharmacy in elderly; Beers criteria; renal dose adjustments.") ] }, { "ch": "36. Drug Prescribing, Regulations & Rational Use", "topics": [ ("Essential Medicines & Rational Prescribing", "WHO essential medicines concept; RNTCP & DOTS; rational drug use principles; prescription writing (Schedule H, H1, X drugs); generic vs brand names; pharmacovigilance & ADR reporting (Yellow Card)."), ("Drug Dependence & Substance Abuse", "Physical vs psychological dependence; drugs of abuse (opioids, benzodiazepines, alcohol, amphetamines, cannabis, LSD); alcohol pharmacology (disulfiram – Antabuse reaction); buprenorphine for opioid dependence.") ] }, ] }, ] # ── PDF Creation ────────────────────────────────────────────────────────────── output_path = "/tmp/workspace/pharma-quiz/MBBS_Pharmacology_High_Yield_Quiz_Topics.pdf" doc = SimpleDocTemplate( output_path, pagesize=A4, rightMargin=2*cm, leftMargin=2*cm, topMargin=2.2*cm, bottomMargin=2*cm, title="MBBS Pharmacology – High-Yield Quiz Topics", author="Orris AI" ) styles = getSampleStyleSheet() # Custom styles title_style = ParagraphStyle( "DocTitle", parent=styles["Title"], fontSize=22, textColor=colors.HexColor("#1a237e"), spaceAfter=6, alignment=TA_CENTER, fontName="Helvetica-Bold" ) subtitle_style = ParagraphStyle( "SubTitle", parent=styles["Normal"], fontSize=11, textColor=colors.HexColor("#455a64"), spaceAfter=4, alignment=TA_CENTER, fontName="Helvetica" ) unit_style = ParagraphStyle( "Unit", parent=styles["Heading1"], fontSize=13, textColor=colors.white, spaceAfter=0, spaceBefore=14, fontName="Helvetica-Bold", backColor=colors.HexColor("#1a237e"), leading=20, leftIndent=-0.3*cm, rightIndent=-0.3*cm, borderPadding=(5, 8, 5, 8), ) chapter_style = ParagraphStyle( "Chapter", parent=styles["Heading2"], fontSize=11, textColor=colors.HexColor("#1a237e"), spaceBefore=10, spaceAfter=4, fontName="Helvetica-Bold", ) topic_title_style = ParagraphStyle( "TopicTitle", parent=styles["Normal"], fontSize=10.5, textColor=colors.HexColor("#b71c1c"), fontName="Helvetica-Bold", spaceAfter=2, spaceBefore=6, ) topic_body_style = ParagraphStyle( "TopicBody", parent=styles["Normal"], fontSize=9.5, textColor=colors.HexColor("#212121"), fontName="Helvetica", leading=14, spaceAfter=4, leftIndent=0.4*cm, ) note_style = ParagraphStyle( "Note", parent=styles["Normal"], fontSize=8.5, textColor=colors.HexColor("#546e7a"), fontName="Helvetica-Oblique", alignment=TA_CENTER, ) story = [] # ── Cover ───────────────────────────────────────────────────────────────────── story.append(Spacer(1, 1.2*cm)) story.append(Paragraph("MBBS Pharmacology", title_style)) story.append(Paragraph("High-Yield Quiz Topics — Complete Syllabus", subtitle_style)) story.append(Paragraph("2 High-Yield Topics Per Chapter | All Units Covered", subtitle_style)) story.append(Spacer(1, 0.3*cm)) story.append(HRFlowable(width="100%", thickness=2, color=colors.HexColor("#1a237e"))) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph( "Prepared for MBBS Phase II / Final Year Pharmacology Quiz Preparation · July 2026", note_style )) story.append(Spacer(1, 0.8*cm)) # ── Table of Contents heading ───────────────────────────────────────────────── toc_title = ParagraphStyle("TocTitle", parent=styles["Normal"], fontSize=12, fontName="Helvetica-Bold", textColor=colors.HexColor("#1a237e"), spaceAfter=6, spaceBefore=4) story.append(Paragraph("Contents at a Glance", toc_title)) story.append(HRFlowable(width="100%", thickness=0.5, color=colors.HexColor("#90a4ae"))) story.append(Spacer(1, 0.2*cm)) toc_entry_style = ParagraphStyle("TocEntry", parent=styles["Normal"], fontSize=9, fontName="Helvetica", textColor=colors.HexColor("#37474f"), spaceAfter=2, leading=13) for unit_data in chapters: story.append(Paragraph(f"<b>{unit_data['unit']}</b>", toc_entry_style)) for ch_data in unit_data["chapters"]: story.append(Paragraph(f"&nbsp;&nbsp;&nbsp;• {ch_data['ch']}", toc_entry_style)) story.append(PageBreak()) # ── Main Content ────────────────────────────────────────────────────────────── for unit_data in chapters: # Unit header bar story.append(Spacer(1, 0.3*cm)) # Coloured table as banner unit_table = Table( [[Paragraph(unit_data["unit"], ParagraphStyle( "UnitBanner", parent=styles["Normal"], fontSize=12, fontName="Helvetica-Bold", textColor=colors.white, leading=16))]], colWidths=[17*cm] ) unit_table.setStyle(TableStyle([ ("BACKGROUND", (0,0), (-1,-1), colors.HexColor("#1a237e")), ("TOPPADDING", (0,0), (-1,-1), 7), ("BOTTOMPADDING", (0,0), (-1,-1), 7), ("LEFTPADDING", (0,0), (-1,-1), 10), ("RIGHTPADDING", (0,0), (-1,-1), 10), ("ROUNDEDCORNERS", [4,4,4,4]), ])) story.append(unit_table) story.append(Spacer(1, 0.3*cm)) for ch_data in unit_data["chapters"]: block_content = [] block_content.append(Paragraph(ch_data["ch"], chapter_style)) block_content.append(HRFlowable(width="100%", thickness=0.5, color=colors.HexColor("#90a4ae"))) for idx, (topic_title, topic_body) in enumerate(ch_data["topics"], 1): num_label = "★" if idx == 1 else "☆" block_content.append( Paragraph(f"{num_label} Topic {idx}: {topic_title}", topic_title_style) ) block_content.append(Paragraph(topic_body, topic_body_style)) story.append(KeepTogether(block_content)) story.append(Spacer(1, 0.1*cm)) story.append(Spacer(1, 0.4*cm)) # ── Footer disclaimer ───────────────────────────────────────────────────────── story.append(HRFlowable(width="100%", thickness=1, color=colors.HexColor("#1a237e"))) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph( "This document covers high-yield topics across all major chapters of the MBBS Pharmacology syllabus (based on MCI/NMC curriculum). " "Topics are selected for their frequency of appearance in university exams and quiz competitions. " "Always cross-reference with your college's prescribed textbooks (Katzung, Rang & Dale, KD Tripathi).", ParagraphStyle("Disclaimer", parent=styles["Normal"], fontSize=8, textColor=colors.HexColor("#78909c"), fontName="Helvetica-Oblique", alignment=TA_JUSTIFY) )) doc.build(story) print(f"PDF saved: {output_path}") PYEOF